Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Moleculin Biotech, Inc. (MBRX : NSDQ)

• Company Description    Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $0.47 Daily Weekly Monthly 20 Day Moving Average: 4,156,869 shares Shares Outstanding: 49.50 (millions) Market Capitalization: $23.04 (millions) Beta: 1.59 52 Week High: $3.33 52 Week Low: $0.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.92% -8.62% 12 Week -31.30% -36.32% Year To Date -72.62% -77.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5300 MEMORIAL DRIVE SUITE 950 - HOUSTON,TX 77007 USA ph: 713-300-5160 fax: - mbrx@jtcir.com http://www.moleculin.com

• General Corporate Information    Officers Walter V. Klemp - Chief Executive Officer and Chairman Jonathan P. Foster - Executive Vice President and Chief Financial Offic Robert George - Director Michael Cannon - Director John Climaco - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 60855D309 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/14/25 Share - Related Items Shares Outstanding: 49.50 Most Recent Split Date: 3.00 (0.07:1) Beta: 1.59 Market Capitalization: $23.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.90 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 78.03% vs. Previous Quarter: 28.99% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -1,498.41 03/31/25 - -278.80 ROA 09/30/25 - - 06/30/25 - -114.47 03/31/25 - -100.11 Current Ratio 09/30/25 - - 06/30/25 - 1.15 03/31/25 - 1.35 Quick Ratio 09/30/25 - - 06/30/25 - 1.15 03/31/25 - 1.35 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - -0.24 03/31/25 - 0.00 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00

Powered by Zacks Investment Research ©